AI Science Tracker
EN

Clinical Oncology School of Fujian Medical University

2 discoveries from 2024

Discoveries

Predictive model of prognosis index for invasive micropapillary carcinoma of the breast based on machine learning: a SEER population-based study.

Source check: Source checked. Not independent scientific confirmation.

Finding: The study develops a prognosis index for 1,123 SEER patients with train/test separation and survival outcomes, a specific cancer-prognosis result. Five ML algorithms (SVM, KNN, RF, Extra Trees, XGBoost) model prognosis from SEER invasive micropapillary breast-carcinoma clinical variables. Testing: 80:20 split, 10-fold internal CV and independent test metrics validate the retrospective prognostic model.. h Source affiliation was not stated in the reviewed case checks and was unavailable in the local bibliographic cache.

Technology: Five ML algorithms (SVM, KNN, RF, Extra Trees, XGBoost) model prognosis from SEER invasive micropapillary breast-carcinoma clinical variables.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Five ML algorithms (SVM, KNN, RF, Extra Trees, XGBoost) model prognosis from SEER invasive micropapillary breast-carcinoma clinical variables.
Test and result
80:20 split, 10-fold internal CV and independent test metrics validate the retrospective prognostic model.
Limitation / still unknown
h
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://link.springer.com/article/10.1186/s12911-024-02669-y

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Identification of prognostic signatures in remnant gastric cancer through an interpretable risk model based on machine learning: a multicenter cohort study.

Source check: Source checked. Not independent scientific confirmation.

Finding: Two hospitals contributed 286 patients, with five-year follow-up; train/validation/test analyses and variable interpretation are reported. An interpretable machine-learning risk model predicts survival in remnant gastric cancer using a multicenter cohort. Testing: Retrospective multicenter cohort; risk estimates are not causal and external validation is still needed.. Source affiliation was not stated in the reviewed case checks and was unavailable in the local bibliographic cache.

Technology: An interpretable machine-learning risk model predicts survival in remnant gastric cancer using a multicenter cohort.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
An interpretable machine-learning risk model predicts survival in remnant gastric cancer using a multicenter cohort.
Test and result
Retrospective multicenter cohort; risk estimates are not causal and external validation is still needed.
Limitation / still unknown
Two hospitals contributed 286 patients, with five-year follow-up; train/validation/test analyses and variable interpretation are reported.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC11062017/unicode · https://europepmc.org/article/MED/38689252

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.